<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tran, Tram</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">The prowess of the nucleotide polymerase inhibitor sofosbuvir (SOF) against hepatitis C virus (HCV) is known. This article presents results from a study investigating a 12-week fixed-dose combination of SOF and nonstructural protein 5A (NS5A) inhibitor GS-5816 regimen in noncirrhotic, treatment-naïve HCV genotype 1 patients.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>